Physicochemical Properties
| Molecular Formula | C27H29CLN2O3 |
| Molecular Weight | 464.99 |
| Exact Mass | 464.187 |
| CAS # | 1233332-14-3 |
| PubChem CID | 59393720 |
| Appearance | Off-white to light yellow solid powder |
| LogP | 6.772 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 7 |
| Heavy Atom Count | 33 |
| Complexity | 662 |
| Defined Atom Stereocenter Count | 2 |
| SMILES | CC1=CC(=CC(=C1C(=O)N[C@@H](C)C(=O)O)C)C2=CC(=CC=C2)N[C@H](C)C3=CC(=C(C=C3)Cl)C |
| InChi Key | KYHUARFFBDLROH-MOPGFXCFSA-N |
| InChi Code | InChI=1S/C27H29ClN2O3/c1-15-11-20(9-10-24(15)28)18(4)29-23-8-6-7-21(14-23)22-12-16(2)25(17(3)13-22)26(31)30-19(5)27(32)33/h6-14,18-19,29H,1-5H3,(H,30,31)(H,32,33)/t18-,19+/m1/s1 |
| Chemical Name | (2S)-2-[[4-[3-[[(1R)-1-(4-chloro-3-methylphenyl)ethyl]amino]phenyl]-2,6-dimethylbenzoyl]amino]propanoic acid |
| Synonyms | NIBR0213 NIBR 0213 NIBR-0213 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | In Ca2+ mobilization tests, NIBR-0213 is inert (IC50 >10 μM) on S1P2, S1P3, and S1P4, but exhibits inhibitory effect on hS1P1 (IC50 of 2.5 nM)[1]. In GTPγ35S tests, NIBR-0213 exhibits strong and similar activity against human and rat S1P1 (IC50 of 2.0 nM and 2.3 nM, respectively), but on mouse S1P1, it has an IC50 of 8.5 nM[1]. In the GTPγ35S test, NIBR-0213 exhibits a selectivity of approximately 3,000 times against human S1P5[1]. The Kd of NIBR-0213, a competitive antagonist of S1P1, is 0.37±0.031 nM [1]. |
| ln Vivo | When rats are given NIBR-0213 orally at a dose of 30 mg/kg, the peripheral blood lymphocyte (PBL) counts are reduced by 75%–85% after 14 hours, and this effect lasts for 24 hours after treatment[1]. When administered therapeutically, NIBR-0213 (30 mg/kg and 60 mg/kg) is effective in a mouse model of experimental autoimmune encephalomyelitis (EAE)[1]. NIBR-0213 exhibits strong oral bioavailability (69%) and moderate clearance (26 mL/min/kg) in its PK characteristics, which result in substantial exposure following oral dosage[1]. |
| Animal Protocol |
Animal/Disease Models: Lewis or Wistar rats (220-250 g, males)[1] Doses: 30 mg/kg Route of Administration: Orally Experimental Results: decreased the PBL counts by 75%-85% within 14 hr and maintained this effect up to 24 hr posttreatment. Animal/Disease Models: C57BL/6 mice bearing EAE model[1] Doses: 30 mg/kg and 60 mg/kg Route of Administration: 30 mg/kg twice per day (BID) for 3 days and then increased to 60 mg/kg BID until the remainder of the experiment. In total, the treatment lasted 26 days Experimental Results: Resulted in a gradual reduction in disease-scores, with a divergence from vehicle controls that became significant after 5 days. |
| References |
[1]. A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis. Chem Biol. 2012 Sep 21;19(9):1142-51. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1506 mL | 10.7529 mL | 21.5058 mL | |
| 5 mM | 0.4301 mL | 2.1506 mL | 4.3012 mL | |
| 10 mM | 0.2151 mL | 1.0753 mL | 2.1506 mL |